FY17. Base award. February 22, 2017 to february 21, 2018. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932.

Ended Definitive Contract Awarded Last action

Contract number
HHSN271201700008C
Awardee
Awarding agency
Obligated
$4,603,109

Award facts

Opportunity
Contract value 41% obligated
  • $4,603,109.46 Current, with exercised options
  • $11,354,157.46 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Richmond, VA 23298, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00016 -$25,476
Funding Only Action P00015 -$80,642
Funding Only Action P00014 -$8,835
Other Administrative Action P00013 $0
Funding Only Action P00012 -$19,698
Other Administrative Action P00011 $0
Other Administrative Action P00010 $0
Exercise an Option P00009 · POP: 2/22/17-2/21/22. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. $1,037,230
Exercise an Option P00008 $93,281
Exercise an Option P00007 · POP: 2/22/17-2/21/21. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. Purpose: to exercise option period 3 (contract year… $875,193
Exercise an Option P00006 $133,677
Exercise an Option P00005 · POP: 2/22/17-2/21/20. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. Purpose: to exercise option period 2 (contract year… $855,528
Exercise an Option 4 · POP: 2/22/17-2/22/19. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. Purpose: to exercise option quantity 9 in… $50,000
Other Administrative Action 3 · FY17. POP: 2/22/17-2/21/19. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. Purpose: to reduce the cost of 1 unit of… $0
Exercise an Option 2 · FY18. POP: february 22, 2017 to february 21, 2019. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. Purpose: to exercise… $836,385
Other Administrative Action 1 · FY17. POP: february 22, 2017 to february 21, 2018. Preclinical medications discovery and abuse liability testing for nida. N01DA-17-8932. Purpose: to remove… $0
Original award $856,466
Show all 17

About this award

This is a cost-reimbursement contract awarded by the National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services, to Virginia Commonwealth University (VCU) for $11,354,157.46. The contract is for preclinical medication discovery and abuse liability testing services in support of NIDA's mission. The contract has a period of performance from February 22, 2017 to February 21, 2018, with a potential completion date of February 16, 2025. This award is not associated with a set-aside program. VCU, a public research university, is the prime contractor and there are no major subcontractors mentioned. This contract contributes to NIDA's broader efforts to develop new treatments for substance abuse and addiction.

Quick answers

Who was awarded contract HHSN271201700008C?

HHSN271201700008C was awarded to Virginia Commonwealth University by National Institute on Drug Abuse (National Institutes of Health) on February 22, 2017.

How much is contract HHSN271201700008C worth?

The government has obligated $4,603,109 on HHSN271201700008C. Its potential value, with all options, is $11,354,157.

Was contract HHSN271201700008C competed?

The extent of competition for HHSN271201700008C was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award